Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A ...

Eligible residents living with diabetes in Saskatchewan who rely on any type of insulin may be eligible to receive coverage ...

DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic health monitoring.

The UBS CIO Americas wealth management equity sector strategy team came out and spotlighted its 30 most preferred stocks ...

The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...

DexCom (NasdaqGS:DXCM) witnessed a 4% increase in its share price over the past week, as the company announced a significant integration of its G7 Continuous Glucose Monitoring Systems with Nanowear's ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NexGel Inc (NXGL – Research Report) and Dexcom ...

DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost ...

Dexcom (Nasdaq:DXCM) has a new chief commercial officer with significant experience at another major medtech company.

DexCom Inc. closed 48.20% below its 52-week high of $142.00, which the company reached on March 26th.

Pioneering the shift from bulky, short-term heart monitors to sleek, wire-free patches, iRhythm Technologies (NASDAQ:IRTC) provides wearable cardiac monitoring devices and AI-powered analysis services ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of $98.00. The ...